Petros Pharmaceuticals (NASDAQ:PTPI) Stock Price Down 4.5% – What’s Next?

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) dropped 4.5% on Tuesday . The stock traded as low as $0.28 and last traded at $0.29. Approximately 138,418 shares changed hands during mid-day trading, a decline of 74% from the average daily volume of 529,558 shares. The stock had previously closed at $0.30.

Petros Pharmaceuticals Trading Down 4.5 %

The stock has a market capitalization of $2.91 million, a P/E ratio of -0.04 and a beta of 2.11. The company has a current ratio of 1.40, a quick ratio of 1.26 and a debt-to-equity ratio of 0.71. The business has a 50-day moving average price of $0.35 and a two-hundred day moving average price of $0.43.

Petros Pharmaceuticals (NASDAQ:PTPI) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.37) earnings per share for the quarter. The company had revenue of $1.42 million for the quarter.

Petros Pharmaceuticals Company Profile

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).